By Jared S. Hopkins
Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company's $590 million contract to help develop a bird-flu vaccine.
Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.
The Trump administration is currently reviewing the contract, according to a person familiar with the matter.
"While it is crucial that the U.S. Department and Health and Human Services support pandemic preparedness, four years of the Biden administration's failed oversight have made it necessary to review agreements for vaccine production," an HHS spokesman said.
A bird-flu outbreak has plagued American farmers, infecting commercial and backyard poultry folks that has contributed to sky-high egg prices and dozens of people getting sick.
Moderna didn't comment on the matter.
Vaxart, another biotech in vaccine development, said recently in a regulatory filing that it received a stop-work order from the federal government regarding a Covid-19 vaccine.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 27, 2025 14:02 ET (19:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。